LAVA’s bispecific gamma-delta T cell engagers (bsTCEs)
directly induce potent killing of tumor cells
via their unique targeting of Vγ9Vδ2 T cells and tumor associated antigens (TAAs).
gd-bsTCEs are fully modular, allowing for usage of Fc and existing antibodies
‘Off the shelf’ manufacturing
They combine a variety of traits to accomplish this including:
High potency with EC50s in low picomolar range
Potential for expansion of activated Vγ9Vδ2 T cells
Avoids the detrimental co-activation of immune-suppressive cells, such as Tregs
Secretion of pro-inflammatory cytokines that attract and activate other cells within the immune system
Antigen presenting capability, potentially triggering an adaptive immune reaction, enabling deep and durable responses
LAVA’s gamma-delta bsTCEs act through multiple mechanisms to induce selective, potent killing of tumor cells
Proof of principle of LAVA’s approach has been established by in vitro, in vivo and ex vivo studies in which gamma-delta bsTCEs demonstrate potent cell death in both tumor cell lines and patient-derived cells in both solid tumors and hematologic malignancies. Based on this data, LAVA is advancing several novel gamma-delta bsTCEs towards clinical development.